Viatris Inc. research snapshot
VTRS AI stock analysis currently reads Viatris Inc. as a global medicines company with established brands, generics, biosimilars, and selected innovative assets. At the July 8, 2026 data cutoff, VTRS traded near $16.51 with an implied market capitalization of about $19.23 billion. The positive case is built on 2026 guidance for $14.7 billion of revenue, $4.3 billion of adjusted EBITDA, $2.40 of adjusted EPS, and $2.15 billion of adjusted free cash flow. The caution case is that GAAP results still carry impairment and restructuring noise, debt is high, growth is modest, and the moat is narrower than a patent-protected specialty pharma leader. This page is informational research, not investment advice.
Current price
$16.51 intraday reference
Market cap
$19.23 billion
AI score
63 / 100
Rating
Cash-generative global pharma platform with low forward multiple, high debt, and turnaround execution risk
Trend status
Constructive uptrend above the 50-day and 200-day moving averages, with momentum positive but not risk-free
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Viatris sells established brands, generics, biosimilars, and selected innovative medicines worldwide, giving it scale and cash flow but only moderate organic growth. | Medium-high |
| Moat | The moat comes from manufacturing scale, regulatory filings, global commercial reach, supply reliability, and complex product know-how, but price competition limits pricing power. | Medium |
| Management | CEO Scott A. Smith and CFO Doretta Mistras are emphasizing portfolio focus, cost savings, capital return, and 2026 growth after the strategic review. | Medium |
| Financial trend | FY2025 revenue was $14.30 billion and FY2025 GAAP net loss was $3.51 billion due mainly to impairment and special items. Q1 2026 revenue rose 8% to $3.52 billion and GAAP net earnings were $176 million. | High |
| Valuation | At $16.51, VTRS screens near 6.7x forward earnings, 1.36x sales, 1.35x book value, 11.0x free cash flow, and about a 2.9% dividend yield. | High |
| Technical trend | StockAnalysis showed VTRS above the 50-day moving average near $16.13 and 200-day moving average near $13.33, with RSI around 60.9. | Medium |
| Risk level | Main risks are debt, generic price erosion, litigation, regulatory quality issues, manufacturing disruptions, product concentration, FX, and over-reliance on adjusted metrics. | Medium-high |
| AI confidence | Descriptive confidence is high because filings and third-party data align on revenue, loss, cash flow, and shares. Return confidence is lower because the market can reprice pharma turnarounds around guidance and safety events. | High data confidence |
| Investment certainty | VTRS may appeal to value-oriented investors if cash flow and debt reduction continue, but it does not yet have the certainty profile of a wide-moat compounder. | Medium |
VTRS AI stock forecast
The VTRS AI stock forecast uses scenarios rather than a single price claim. Using the $16.52 verification price and the $2.40 midpoint of 2026 adjusted EPS guidance, the audited three-year framework produced about $10.6 in a bear case, $17.8 in a base case, and $23.5 in a bullish case before dividends. Because GAAP EPS is currently negative on a TTM basis, these ranges should be treated as normalized-earnings stress tests, not price promises.
$22 to $25 before dividends
More likely if revenue grows near or above the 2026 midpoint, adjusted EBITDA reaches the $4.3 billion midpoint, new products contribute meaningfully, debt falls, and the market gives VTRS an 8x normalized EPS multiple.
$16 to $19 before dividends
More likely if Viatris delivers 2026 guidance, generic price pressure stays manageable, free cash flow remains near guidance, and investors keep valuing the company around a high-single-digit adjusted earnings multiple.
$10 to $12 before dividends
More likely if adjusted earnings decline, debt reduction slows, price erosion worsens, manufacturing or quality issues hit supply, litigation costs rise, or the market refuses to give credit for adjusted metrics.
VTRS AI technical analysis
VTRS AI technical analysis is constructive as of the July 8, 2026 data cutoff. StockAnalysis showed a real-time price near $16.51, market cap near $19.23 billion, a 50-day moving average near $16.13, a 200-day moving average near $13.33, RSI near 60.9, and 20-day average volume above 10 million shares. Investing.com also showed daily moving-average signals leaning buy, though its RSI snapshot was lower. The setup is positive, but a sustained break below the 50-day area would reduce confidence.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $16.51 intraday | StockAnalysis listed this real-time reference on July 8, 2026 during market hours. |
| Immediate support | $16.00 to $16.15 | This range brackets the 50-day moving average near $16.13 and recent consolidation support. |
| Deeper support | $13.30 to $14.00 | This range brackets the 200-day moving average near $13.33 and would be a larger trend review zone. |
| Near resistance | $17.50 to $18.00 | Recent 52-week highs and the base-case scenario zone make this the first resistance area. |
| Upper resistance | $22 to $25 | This bullish scenario range likely requires guidance delivery, debt reduction, and better confidence in sustainable adjusted earnings. |
| Moving averages | 50-day near $16.13, 200-day near $13.33 | Trading above both averages supports the current uptrend, but a close below the 50-day average would weaken the setup. |
| Momentum | RSI near 60.9 on StockAnalysis | Momentum is positive but not at an extreme reading, so confirmation should come from price holding support and earnings catalysts. |
| Volume | 20-day average near 10.3 million shares | Liquidity is adequate for a large-cap healthcare stock, but volume should be watched around earnings, FDA news, supply events, and debt updates. |
| Volatility | Earnings and guidance sensitive | The next confirmed earnings date was listed as August 6, 2026, which can reset the technical range. |
| Invalidation | Close below $16, then below $13.30 | A close below the 50-day area weakens trend-following confidence. A break below the 200-day area would challenge the larger recovery trend. |
VTRS AI trading strategy
The VTRS AI trading strategy below is a rules-based research framework, not personal advice. It connects price levels with revenue guidance, adjusted EBITDA, adjusted EPS, free cash flow, debt reduction, product launches, quality events, litigation, and generic pricing pressure.
Watch for VTRS to hold the $16.00 to $16.15 support area and keep trading above the 50-day moving average while Q2 results confirm revenue growth, adjusted EBITDA, adjusted EPS, free cash flow, and debt reduction.
A close below $16 should reduce trend confidence, especially if management lowers guidance, new product revenue disappoints, or debt metrics stop improving.
If VTRS pulls back toward the $13.30 to $14.00 long-term support area without a break in cash flow or guidance, compare the lower price with normalized EPS, free cash flow yield, dividend coverage, and leverage.
Do not treat the stock as cheap based only on forward PE if GAAP earnings, debt, regulatory issues, or manufacturing disruptions point to a lower-quality earnings base.
Track 2026 revenue guidance, adjusted EBITDA, adjusted EPS, free cash flow, net debt, debt maturities, product launch revenue, Greater China growth, generics price erosion, FDA or quality updates, and litigation settlements.
Position sizing should reflect that VTRS is a leveraged healthcare value and execution story, not a guaranteed dividend stock or a precise AI price prediction.
Investment research summary
Viatris gets paid because patients, pharmacies, governments, and healthcare systems need reliable access to established medicines, generics, biosimilars, and selected specialty products at global scale.
The moat is based on regulatory know-how, manufacturing scale, broad market access, supply reliability, complex product filings, and global distribution. It is real but narrower than a high-IP specialty pharma moat because many products face price competition.
The thesis fails if adjusted earnings mask weak GAAP economics, debt remains high, generic price erosion accelerates, quality or manufacturing events hurt supply, litigation costs absorb cash, or new products fail to offset mature-product pressure.
Scott A. Smith is leading the post-review strategy, with Doretta Mistras focused on capital allocation and financial discipline. The key test is whether cost savings and reinvestment improve durable growth rather than only short-term adjusted EPS.
Global healthcare demand and access to affordable medicine are long-term tailwinds. The offset is that mature generic and branded portfolios face payer pressure, regulatory scrutiny, FX, patent cliffs, and manufacturing execution risk.
At roughly 6.7x forward earnings and about 11x free cash flow, VTRS looks inexpensive if adjusted earnings convert to debt reduction and shareholder returns. Margin of safety is weaker if GAAP losses, special charges, or pricing pressure persist.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| VTRS quote reference | $16.51 intraday on July 8, 2026 | StockAnalysis VTRS market cap page | July 8, 2026 |
| Market capitalization verification | $19.23 billion reported and $19.24 billion calculated from $16.52 x 1.1646 billion shares | Pineify financial_rigor.py and StockAnalysis | July 8, 2026 |
| Shares outstanding | 1.16 billion shares outstanding, down 2.61% year over year | StockAnalysis VTRS statistics | July 8, 2026 |
| FY2025 revenue | $14.30 billion total revenue, cross-checked with StockTitan and StockAnalysis | Viatris FY2025 results | July 8, 2026 |
| FY2025 GAAP net loss | $3.51 billion net loss, mainly affected by a $2.9 billion goodwill impairment | Viatris FY2025 results | July 8, 2026 |
| Q1 2026 revenue and net earnings | $3.52 billion revenue and $176 million GAAP net earnings for Q1 2026 | Viatris Q1 2026 earnings release | July 8, 2026 |
| 2026 guidance midpoint | $14.7 billion revenue, $4.3 billion adjusted EBITDA, $2.40 adjusted EPS, and $2.15 billion adjusted free cash flow | Viatris Q1 2026 earnings release | July 8, 2026 |
| Cash and restricted cash | $1.806 billion at March 31, 2026; StockAnalysis cash-only data aligns at about $1.804 billion | SEC Form 10-Q for Q1 2026 | July 8, 2026 |
| TTM free cash flow | $1.79 billion TTM free cash flow and about $1.54 free cash flow per share | StockAnalysis VTRS statistics | July 8, 2026 |
| Technical indicators | 50-day moving average near $16.13, 200-day moving average near $13.33, RSI near 60.9 | StockAnalysis VTRS statistics | July 8, 2026 |
This VTRS AI stock analysis is an informational research tool only. It is not investment advice, not a recommendation to buy or sell Viatris Inc., and not a promise of future returns. Forecasts are scenario-based estimates from available public data and can be wrong.
